Skip to content

The comparison of analgesia effects of morphine pump between in the cisterna magna and thoracic/lumbar subarachnoid space on patients with cancer pain: a pilot multicenter study

The comparison of analgesia effects of morphine pump between in the cisterna magna and thoracic/lumbar subarachnoid space on patients with cancer pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-17010681
Enrollment
Unknown
Registered
2017-02-19
Start date
2009-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

programmable morphine pump in the cisterna magna:the implantation of a programmable morphine pump at the level of the cisterna magna
programmable morphine pump in the thoracic/lumbar subarachnoid space:the implantation of a programmable morphine pump at the level of the thoracic/lumbar subarachnoid space
patient-controlled intrathecal analgesia in the thoracic/lumbar subarachnoid space:the implantation of patient-controlled intrathecal analgesia at the level of the thoracic/lumbar subarachnoid space

Sponsors

Chinese General Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The score of visual analogue scale = 7; 2. Inadequate analgesia by high dose oral opioids (equivalent to morphine 400mg/d) or intolerable side effects; 3. life expectancy = 3 months; 4. The results of screening test were positive; 5. High tolerance of general anesthesia; 6. Besides the above criteria (1-5), patients in cisterna magna group also had upper thoracic or cervical tumor/metastases; 7. Besides the above criteria (1-5), patients in conventional region group also had neither upper thoracic nor cervical tumor/metastases.

Exclusion criteria

Exclusion criteria: 1. Allergy to opioids; 2. Puncture site with infection; 3. With anticoagulant therapy or coagulation disorders; 4. With Brain metastases, paraplegia or other serious diseases; 5. Communication disorders or cognitive impairment ; 6. Significant obstruction of the spinal canal by the tumor.

Design outcomes

Primary

MeasureTime frame
pain intensity by VAS score;life quality assessment by SF-36 score;morphine usage before operation (converted to oral morphine);morphine usage from pump in 24h after operation (VAS score<3);depression assessment by SDS score;

Secondary

MeasureTime frame
side effects;

Countries

China

Contacts

Public ContactYonghai Sun

Chinese General Hospital of PLA

13552265533@163.com+86 13552265533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026